Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androge...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
1999
|
| Rochtain ar líne: | https://doi.org/10.1038/sj.bjc.6690684 https://www.nature.com/articles/6690684.pdf |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|